China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences Co., Ltd. The alliance aims to leverage their respective advantageous resources to promote the research and development of CPX102, an interleukin-29 (IL-29) program from Sino Biopharmaceutical. Specifically, the two companies will carry out exclusive licensing and collaboration related to the product in Greater China (including Hong Kong, Macau, and Taiwan), Brazil, Saudi Arabia, Thailand, and Singapore, among a total of 19 countries. No financial details were disclosed.
Product Details
CPX102, a protein-engineered optimized nebulized inhalation solution, is essentially a type III interferon. It does not directly kill or inhibit viruses but instead inhibits virus replication by inducing cell surface receptors to promote the cells’ production of antiviral proteins. Moreover, CPX102 can activate natural autoimmunity by regulating immune cells such as cytotoxic T cells (CTL cells), natural killer cells (NK cells), and macrophages to achieve antiviral effects. The product is currently undergoing a Phase Ib study in China for the treatment of respiratory syncytial virus (RSV) infection in children.-Fineline Info & Tech
Leave a Reply